EMEA-002029-PIP01-16-M03
Key facts
Active substance |
Tremelimumab
|
Therapeutic area |
Oncology
|
Decision number |
P/0367/2022
|
PIP number |
EMEA-002029-PIP01-16-M03
|
Pharmaceutical form(s) |
Concentrate for solution for infusion
|
Condition(s) / indication(s) |
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
AstraZeneca AB
Tel. +46 8553 27591 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|